Overview

Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19

Status:
Recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
Currently COVID-19 is an international public health emergency. Most COVID-19 patients have mild or uncomplicated disease, but approximately 14% develop severe disease that requires hospitalization and oxygen therapy, and up to 5% of patients require admission to Intensive Care Units. To date, the only treatments that have shown efficacy in a clinical trial are remdesivir and dexamethasone. The main objective is to provide reliable estimates on the effects of different treatment strategies on the outcome and mortality of patients with SARS-CoV-2 infection.
Phase:
Phase 3
Details
Lead Sponsor:
Instituto de Investigación Hospital Universitario La Paz
Treatments:
BB 1101
Dexamethasone
Dexamethasone acetate
Emtricitabine
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Tenofovir